Page 213 - HIV/AIDS Guidelines

Table 16b. Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors*, Maraviroc,
Raltegravir, and Protease Inhibitors* (Page 3 of 3)

EFV ETR NVP RPV a MVC RAL

PK ↓ RPV possible ↓ RPV possible ↓ RPV possible No data No data
data
RPV •
Do not coadminister. Do not coadminister. Do not No data No data
Dose
coadminister.
With RTV 100 mg With RTV 100
PK Refer to BID mg BID
RTV data Refer to information Refer to information Refer to information information MVC: AUC ↑ 161% RAL: AUC ↓
for boosted PI. for boosted PI. for boosted PI. for boosted 16%
PI.
Dose MVC 150 mg BID Standard
With SQV 1200 mg TID With (SQV 1000 mg + With 600 mg TID ↑ RPV With (SQV 1000 No data
SQV: AUC ↓ 62% RTV 100 mg) BID SQV: AUC ↓ 24% possible mg + RTV 100 mg)
EFV: AUC ↓ 12% SQV: AUC unchanged NVP: no significant BID
SQV – PK ETR: AUC ↓ 33%, change MVC: AUC ↑ 877%
always data C min ↓ 29% With (SQV 1000
use Reduced ETR levels mg + RTV 100 mg)
with similar to reduction BID + EFV
RTV with DRV/r
MVC: AUC ↑ 400%
(SQV 1000 mg + (SQV 1000 mg + Dose with SQV/r not Standard MVC 150 mg BID Standard
Dose
RTV 100 mg) BID RTV 100 mg) BID established
With (TPV 500 mg + With (TPV 500 mg + With (TPV 250 mg + ↑ RPV With (TPV 500 mg With (TPV 500
RTV 100 mg) BID RTV 200 mg) BID RTV 200 mg) BID possible + RTV 200 mg) mg + RTV 200
TPV: AUC ↓ 31%, ETR: AUC ↓ 76%, and with (TPV 750 BID mg) BID
C min ↓ 42% C min ↓ 82% mg + RTV 100 mg) MVC: no RAL: AUC ↓
EFV: no significant TPV: AUC ↑ 18%, BID significant change 24%
TPV – change C ↑ 24% NVP: no significant in AUC
always PK min change TPV: no data
use data With (TPV 750 mg + TPV: no data
with RTV 200 mg) BID
RTV TPV: no significant
change
EFV: no significant
change
Dose Standard Do not coadminister. Standard Standard MVC 300 mg BID Standard

a
Approved dose for RPV is 25 mg once daily. Most PK interaction studies were performed using 75 to 150 mg per dose.
b Based on between-study comparison.
c
Use a combination of two LPV/r 200 mg/50 mg tablets + one LPV/r 100 mg/25 mg tablet to make a total dose of LPV/r 500 mg/125 mg.
Key to Abbreviations: APV = amprenavir, ART = antiretroviral therapy, ATV = atazanavir, AUC = area under the curve, BID = twice daily,
C max = maximum plasma concentration, C min = minimum plasma concentration, CYP = cytochrome P, DLV = delavirdine, DRV = darunavir,
DRV/r = darunavir/ritonavir, EFV = efavirenz, ETR = etravirine, FDA = Food and Drug Administration, FPV = fosamprenavir, IDV = indinavir,
LPV = lopinavir, LPV/r = lopinavir/ritonavir, MVC = maraviroc, NFV = nelfinavir, NVP = nevirapine, PI = protease inhibitor,
PK = pharmacokinetic, RAL = raltegravir, RPV = rilpivirine, RTV = ritonavir, SQV = saquinavir, SQV/r = saquinarir/ritonavir, TID = three times a
day, TPV = tipranavir

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-43

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.